20-079 Phase I
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies (View details on clinicaltrial.gov)
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (View details on clinicaltrial.gov)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (View details on clinicaltrial.gov)
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the Treatment of Advanced Solid Tumors with MAPK Pathway Mutations (View details on clinicaltrial.gov)
A Phase 1, Open Label, Dose Escalation Study of RLY-1971 in Subjects with Advanced or Metastatic Solid Tumors (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multicenter, Dose Escalation Study or MRNA-2416, A Lipid Nanoparticle Encapsulated MRNA Encoding Human OX4OL, For Intratumoral Injection to Patients with Advanced Malignancies (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies (View details on clinicaltrial.gov)